Journal
IMMUNOLOGY LETTERS
Volume 166, Issue 2, Pages 87-91Publisher
ELSEVIER
DOI: 10.1016/j.imlet.2015.05.019
Keywords
Granzyme A; IFN-gamma; IGRA tests; Tuberculosis; Infection; Disease
Categories
Funding
- Norwegian Agency for Development Cooperation (NORAD) through Tuberculosis Vaccine Initiative (TBVI) [1001143436007833]
- European Commission within the 7th Framework Programme
- NEWTBVAC [HEALTH-F3-2009-241745]
- Horizon2020 Programme
- TBVAC2020 [643381]
Ask authors/readers for more resources
Cytotoxic molecules such as granulysin, perforin and granzymes produced by cytolytic T cells directly contribute to immune defense against tuberculosis (TB). In search for novel TB biomarkers, we have evaluated the levels of granzyme A in plasma obtained from QuantiFERON-TB Gold In tube (QFT-IT) assays from patients with active TB disease and subjects with latent TB infection (LTBI). Granzyme A serum levels in TB patients were significantly lower than values found in LTBI subjects even after subtraction of the unstimulated levels from the antigen-stimulated responses. The receiver operator characteristics (ROC) curve analysis comparing TB patients and LTBI groups, showed that at a cut-off value of granzyme A of <3.425pg/ml, the sensitivity and the specificity of the assay were 29.41% and 94.74%, respectively. Our results suggest that granzyme A could be considered another biomarker of TB, that can be used, other than IFN-gamma, to discriminate between patients with active TB and LTBI subjects in a well characterized cohort of confirmed Mycobacterium tuberculosis-infected individuals. (C) 2015 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available